- Home
- TLS vs ACIU Comparison
TLS vs ACIU Comparison
Compare TLS & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLS
- ACIU
- Stock Information
- Founded
- TLS 1969
- ACIU 2003
- Country
- TLS United States
- ACIU Switzerland
- Employees
- TLS N/A
- ACIU N/A
- Industry
- TLS EDP Services
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- TLS Technology
- ACIU Health Care
- Exchange
- TLS Nasdaq
- ACIU Nasdaq
- Market Cap
- TLS 306.7M
- ACIU 305.7M
- IPO Year
- TLS 2020
- ACIU 2016
- Fundamental
- Price
- TLS $3.27
- ACIU $3.27
- Analyst Decision
- TLS Buy
- ACIU Strong Buy
- Analyst Count
- TLS 6
- ACIU 2
- Target Price
- TLS $4.80
- ACIU $12.00
- AVG Volume (30 Days)
- TLS 706.7K
- ACIU 131.4K
- Earning Date
- TLS 11-12-2024
- ACIU 11-05-2024
- Dividend Yield
- TLS N/A
- ACIU N/A
- EPS Growth
- TLS N/A
- ACIU N/A
- EPS
- TLS N/A
- ACIU N/A
- Revenue
- TLS $122,959,000.00
- ACIU $48,505,404.00
- Revenue This Year
- TLS N/A
- ACIU N/A
- Revenue Next Year
- TLS $43.60
- ACIU $938.44
- P/E Ratio
- TLS N/A
- ACIU N/A
- Revenue Growth
- TLS N/A
- ACIU 4097200.00
- 52 Week Low
- TLS $1.89
- ACIU $2.25
- 52 Week High
- TLS $5.03
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- TLS 37.85
- ACIU 54.88
- Support Level
- TLS $3.65
- ACIU $3.11
- Resistance Level
- TLS $4.82
- ACIU $3.41
- Average True Range (ATR)
- TLS 0.29
- ACIU 0.23
- MACD
- TLS -0.12
- ACIU 0.03
- Stochastic Oscillator
- TLS 5.81
- ACIU 46.72
About TLS Telos Corporation
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.